Assessment of management options on striga infestation and maize grain yield in Kenya

Published online: 04 April 2018The parasitic purple witchweed [Striga hermonthica (Del.) Benth.] is a serious constraint to maize production in sub-Saharan Africa, especially in poor soils. Various Striga spp. control measures have been developed, but these have not been assessed in an integrated system. This study was conducted to evaluate a set of promising technologies for S. hermonthica management in western Kenya. We evaluated three maize genotypes either intercropped with peanut (Arachis hypogaea L.), soybean [Glycine max (L.) Merr.], or silverleaf desmodium [Desmodium uncinatum (Jacq.) DC] or as a sole crop at two locations under artificial S. hermonthica infestation and at three locations under natural S. hermonthica infestation between 2011 and 2013. Combined ANOVA showed significant (P<0.05) cropping system and cropping system by environment interactions for most traits measured. Grain yield was highest for maize grown in soybean rotation (3,672 kg ha−1) under artificial infestation and in D. uncinatum and peanut cropping systems (3,203 kg ha−1 and 3,193 kg ha−1) under natural infestation. Grain yield was highest for the Striga spp.-resistant hybrid under both methods of infestation. A lower number of emerged S. hermonthica plants per square meter were recorded at 10 and 12 wk after planting on maize grown under D. uncinatum in the artificial S. hermonthica infestation. A combination of herbicide-resistant maize varieties intercropped with legumes was a more effective method for S. hermonthica control than individual-component technologies. Herbicide-resistant and Striga spp.-resistant maize integrated with legumes would help reduce the Striga spp. seedbank in the soil. Farmers should be encouraged to adopt an integrated approach to control Striga spp. for better maize yields

Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria

Background and objectives: This report summarizes the first phase 1 trial treating patients with microalbuminuric diabetic kidney disease (DKD) using FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF). CTGF is critically involved in processes of progressive fibrosis, including DKD. This phase 1, open-label, dose-escalation trial evaluated safety, pharmacokinetics, and possible therapeutic effects of FG-3019 on albuminuria, proteinuria, and tubular proteins

Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement

Current American Thoracic Society (ATS) standards promote the use of race and ethnicity-specific reference equations for pulmonary function test (PFT) interpretation. There is rising concern that the use of race and ethnicity in PFT interpretation contributes to a false view of fixed differences between races and may mask the effects of differential exposures. This use of race and ethnicity may contribute to health disparities by norming differences in pulmonary function. In the United States and globally, race serves as a social construct that is based on appearance and reflects social values, structures, and practices. Classification of people into racial and ethnic groups differs geographically and temporally. These considerations challenge the notion that racial and ethnic categories have biological meaning and question the use of race in PFT interpretation. The ATS convened a diverse group of clinicians and investigators for a workshop in 2021 to evaluate the use of race and ethnicity in PFT interpretation. Review of evidence published since then that challenges current practice and continued discussion concluded with a recommendation to replace race and ethnicity-specific equations with race-neutral average reference equations, which must be accompanied with a broader re-evaluation of how PFTs are used to make clinical, employment, and insurance decisions. There was also a call to engage key stakeholders not represented in this workshop and a statement of caution regarding the uncertain effects and potential harms of this change. Other recommendations include continued research and education to understand the impact of the change, to improve the evidence for the use of PFTs in general, and to identify modifiable risk factors for reduced pulmonary function

Hospitalizations in patients with idiopathic pulmonary fibrosis

Abstract Background Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF. Methods The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models. Results A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater. Conclusions Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT0191551